Driving down turnaround times (TATs), to enable more rapid diagnosis and treatment of patients, is the key philosophy of Source BioScience. As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK, Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from its preferred partner, Philips.
As cancer cases continue to increase among a growing and ageing population and a cash-constrained NHS faces the challenge to sign-off on large capital expenditure projects, the introduction of digital pathology at Source BioScience further enhances the partnership with private- and government-funded hospitals throughout the UK to meet the TATs demanded by governing bodies.
With access to a team of over 60 leading consultant pathologists, Source BioScience is able to reduce TATs for hospitals to report back to patients, such as those waiting on the results of their biopsies, to meet the two-week wait (TWW) target issued by the NHS governing body. The introduction of digital pathology to the company’s suite of services will further enhance these capabilities.
Operating from an ISO-accredited, state-of-the-art laboratory at its headquarters in Nottingham, Source BioScience has the ability to provide digitised images of tissue taken from patient biopsies to over 100 hospitals across the UK and Ireland, which will lead to an improved service to NHS hospitals and private healthcare providers in cancer diagnosis and treatment.